Editas-Logo-Small (1).jpg
Editas Medicine Names Cynthia Collins to Board of Directors
December 10, 2018 09:00 ET | Editas Medicine, Inc.
CAMBRIDGE, Mass., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it has appointed Cynthia Collins to its Board of...
Editas-Logo-Small (1).jpg
Editas Medicine Announces Pre-Clinical Data Supporting Novel Approach for Treatment of Sickle Cell Disease and Beta-Thalassemia
December 02, 2018 19:35 ET | Editas Medicine, Inc.
CAMBRIDGE, Mass., Dec. 02, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced results from experiments to demonstrate expanded CRISPR...
Editas-Logo-Small (1).jpg
Editas Medicine Announces FDA Acceptance of IND Application for EDIT-101
November 30, 2018 07:30 ET | Editas Medicine, Inc.
EDIT-101 set to be the first in vivo CRISPR medicine administered to people anywhere in the world Earns $25 million milestone for IND acceptance from partner Allergan CAMBRIDGE, Mass., Nov. 30,...
Editas-Logo-Small (1).jpg
Editas Medicine Announces Third Quarter 2018 Results and Update
November 07, 2018 16:01 ET | Editas Medicine, Inc.
Filed IND application for EDIT-101 with FDA in October Favorable Appeals Court ruling affirms strength of foundational intellectual property Oral presentation at ASH Annual Meeting to highlight...
Editas-Logo-Small (1).jpg
Editas Medicine to Host Conference Call Discussing Third Quarter 2018 Corporate Update and Results
October 31, 2018 16:01 ET | Editas Medicine, Inc.
CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on...
Editas-Logo-Small (1).jpg
Editas Medicine Grows Scientific Leadership with Two New Appointments
October 01, 2018 09:00 ET | Editas Medicine, Inc.
CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that Richard A. Morgan, Ph.D., a leading expert in gene...
Editas-Logo-Small (1).jpg
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Affirms Favorable U.S. Patent and Trademark Office Decision in CRISPR Interference
September 10, 2018 13:58 ET | Editas Medicine, Inc.
CAMBRIDGE, Mass., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, announced today that the U.S. Court of Appeals for the Federal Circuit...
Editas-Logo-Small (1).jpg
Editas Medicine Announces Transition of Chief Medical Officer
August 27, 2018 16:01 ET | Editas Medicine, Inc.
CAMBRIDGE, Mass., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, today announced that its Chief Medical Officer, Gerald Cox, M.D., Ph.D.,...
Editas-Logo-Small (1).jpg
Editas Medicine Announces the Completion of the Recombinant DNA Advisory Committee (RAC) Registration Process
August 16, 2018 16:01 ET | Editas Medicine, Inc.
CAMBRIDGE, Mass., Aug. 16, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, announced today the National Institutes of Health (NIH) Recombinant DNA...
Editas-Logo-Small (1).jpg
Editas Medicine Announces Second Quarter 2018 Results and Update
August 06, 2018 16:05 ET | Editas Medicine, Inc.
Allergan exercises option to develop and commercialize EDIT-101 globally and Editas exercises option to co-develop and equally share profits and losses in the United States Plan to file EDIT-101...